tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CERo Therapeutics Faces Nasdaq Delisting Risk

Story Highlights
CERo Therapeutics Faces Nasdaq Delisting Risk

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from CERo Therapeutics Holdings ( (CERO) ).

On August 28, 2025, CERo Therapeutics Holdings received a notification from Nasdaq regarding non-compliance with the minimum stockholders’ equity requirement of $2,500,000, risking suspension and delisting of its securities. The company has requested a hearing to present a plan to regain compliance, potentially through financing transactions, although there is no assurance of success.

The most recent analyst rating on (CERO) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.

More about CERo Therapeutics Holdings

CERo Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutic solutions.

Average Trading Volume: 1,119,128

Technical Sentiment Signal: Sell

Current Market Cap: $8.92M

For an in-depth examination of CERO stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1